JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

Anesth Analg 2009; 108:1964-1966
© 2009 International Anesthesia Research Society
doi: 10.1213/ane.0b013e3181a2b5e8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kitamura, T.
Right arrow Articles by Yamada, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kitamura, T.
Right arrow Articles by Yamada, Y.
Related Collections
Right arrow Mechanisms
Right arrow Pain Mechanisms
Right arrow Preclinical Pharmacology
Right arrow Pain
Right arrow Pharmacology

ANALGESIA

The Individual and Combined Effects of U50,488, and Flurbiprofen Axetil on Visceral Pain in Conscious Rats

Takayuki Kitamura, MD, Makoto Ogawa, MD, and Yoshitsugu Yamada, MD, PhD

From the Department of Anesthesiology, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Address correspondence and reprint requests to Takayuki Kitamura, MD, Department of Anesthesiology, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan 113-8655. Address e-mail to tyy-kitamura{at}m7.dion.ne.jp.

Abstract

We examined the effects of U50,488, a kappa-opioid receptor agonist, and flurbiprofen axetil, a nonsteroidal antiinflammatory drug, in a visceral pain model using conscious rats. U50,488 produced visceral antinociception, but exaggerated the adverse effects on the central nervous system (CNS) at 0.9 mg/kg or more. Naloxone completely antagonized these effects. Flurbiprofen axetil produced visceral antinociception, but exaggerated the adverse effects on the CNS at 80 mg/kg. Coadministration of U50,488 (0.27 mg/kg) and flurbiprofen axetil (50 mg/kg) produced intense visceral antinociception without adverse effects on the CNS, implying therapeutic efficacies of coadministration of kappa-opioid receptor-agonists and nonsteroidal antiinflammatory drugs on visceral pain.






Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2009 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2009 by the International Anesthesia Research Society.